Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.
The company, a leading manufacturer of CPAP machines used to treat sleep apnea, faces a nuanced challenge from GLP-1-based medications. The core issue: obesity drives the vast majority of obstructive sleep apnea cases, with 70-90% of sufferers experiencing the condition due to excess weight. As patients lose weight through GLP-1 treatments, their need for breathing assistance devices may disappear entirely.
Source Fool.com
Resmed Inc. Aktie
217,10 €
-0,73 %
Starke Bevorzugung von Resmed Inc. in der Community mit ausschließlich Buy-Einschätzungen.
Ein positives, wenn auch nicht starkes, Potenzial für Resmed Inc. mit einem Kursziel von 259 € im Vergleich zu 217.1 €.
